M
Markus Ball
Researcher at University of Cologne
Publications - 37
Citations - 1804
Markus Ball is an academic researcher from University of Cologne. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 15, co-authored 28 publications receiving 1289 citations. Previous affiliations of Markus Ball include University of South Florida & University of Tübingen.
Papers
More filters
Journal ArticleDOI
New insights into the Tyrolean Iceman's origin and phenotype as inferred by whole-genome sequencing
Andreas Keller,Angela Graefen,Markus Ball,Mark Matzas,Valesca Boisguerin,Frank Maixner,Petra Leidinger,Christina Backes,Rabab Khairat,Michael Forster,Bjoern Stade,Andre Franke,Jens Mayer,Jessica Spangler,Stephen F. McLaughlin,Minita Shah,Clarence Lee,Timothy T. Harkins,Alexander Sartori,Andrés Moreno-Estrada,Brenna M. Henn,Martin Sikora,Ornella Semino,Jacques Chiaroni,Siiri Rootsi,Natalie M. Myres,Vicente M. Cabrera,Peter A. Underhill,Carlos Bustamante,Eduard Egarter Vigl,Marco Samadelli,Giovanna Cipollini,Jan Haas,Hugo A. Katus,Brian O'Connor,Marc R. J. Carlson,Benjamin Meder,Nikolaus Blin,Nikolaus Blin,Eckart Meese,Carsten M. Pusch,Albert Zink +41 more
TL;DR: The complete genome sequence of the Iceman is reported and 100% concordance between the previously reported mitochondrial genome sequence and the consensus sequence generated from the genomic data is shown.
Journal ArticleDOI
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
Kelly L. Bolton,Ryan Ptashkin,Teng Gao,Lior Z. Braunstein,Sean M. Devlin,Daniel Kelly,Minal Patel,Antonin Berthon,Aijazuddin Syed,Mariko Yabe,Catherine C. Coombs,Nicole M. Caltabellotta,Michael Walsh,Kenneth Offit,Zsofia K. Stadler,Diana Mandelker,Jessica Schulman,Akshar Patel,John Philip,Elsa Bernard,Gunes Gundem,Juan E. Arango Ossa,Max Levine,Juan S. Medina Martinez,Noushin Farnoud,Dominik Glodzik,Sonya Li,Mark E. Robson,Choonsik Lee,Paul D.P. Pharoah,Konrad H. Stopsack,Barbara Spitzer,Simon Mantha,James A. Fagin,Laura Boucai,Christopher J. Gibson,Benjamin L. Ebert,Andrew L. Young,Todd E. Druley,Koichi Takahashi,Nancy K. Gillis,Markus Ball,Eric Padron,David M. Hyman,David M. Hyman,José Baselga,Larry Norton,Larry Norton,Stuart Gardos,Stuart Gardos,Virginia M. Klimek,Virginia M. Klimek,Howard I. Scher,Howard I. Scher,Dean F. Bajorin,Dean F. Bajorin,Eder Paraiso,Ryma Benayed,Maria E. Arcila,Marc Ladanyi,David B. Solit,Michael F. Berger,Martin S. Tallman,Montserrat Garcia-Closas,Nilanjan Chatterjee,Luis A. Diaz,Ross L. Levine,Lindsay M. Morton,Ahmet Zehir,Elli Papaemmanuil +69 more
TL;DR: It is found mutations are selected differentially based on exposures, whereas cancer therapy with radiation, platinum and topoisomerase II inhibitors preferentially selects for mutations in DNA damage response genes (TP53, PPM1D, CHEK2).
Journal ArticleDOI
Ancestry and pathology in King Tutankhamun's family
Zahi Hawass,Yehia Z. Gad,Somaia Ismail,Rabab Khairat,Dina Fathalla,Naglaa Hasan,Amal Ahmed,Hisham Elleithy,Markus Ball,Fawzi Gaballah,Sally Wasef,Mohamed Fateen,Hany Amer,Paul Gostner,Ashraf Selim,Albert Zink,Carsten M. Pusch +16 more
TL;DR: Use of a multidisciplinary scientific approach showed the feasibility of gathering data on Pharaonic kinship and diseases and speculated about individual causes of death in Tutankhamun.
Journal ArticleDOI
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study
Nancy K. Gillis,Markus Ball,Qing Zhang,Zhenjun Ma,YuLong Zhao,Sean J. Yoder,Maria E. Balasis,Tania Mesa,David A. Sallman,Jeffrey E. Lancet,Rami S. Komrokji,Alan F. List,Howard L. McLeod,Melissa Alsina,Rachid Baz,Kenneth H. Shain,Dana E. Rollison,Eric Padron +17 more
TL;DR: The prevalence of CHIP in all patients was higher than has been reported in elderly individuals without cancer and the primary exposure was CHIP, suggesting that mutation-specific differences might exist in therapy-related myeloid neoplasm risk.
Journal ArticleDOI
Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
Akihide Yoshimi,Maria E. Balasis,Alexis Vedder,Kira Feldman,Yan Ma,Hailing Zhang,Stanley Chun-Wei Lee,Christopher Letson,Sandrine Niyongere,Sydney X. Lu,Markus Ball,Justin Taylor,Qing Zhang,YuLong Zhao,Salma Youssef,Young Rock Chung,Xiao Jing Zhang,Benjamin H. Durham,Wendy Yang,Alan F. List,Mignon L. Loh,Virginia M. Klimek,Michael F. Berger,Elliot Stieglitz,Eric Padron,Omar Abdel-Wahab +25 more
TL;DR: Engraftment of CMML and JMML resulted in overt phenotypic abnormalities and lethality in recipients, which facilitated evaluation of the JAK2/FLT3 inhibitor pacritinib in vivo, allowing creation of genetically accurate preclinical models of these disorders.